Real‐World Insights Into cN3 Larynx and Hypopharynx Cancer: Treatment Modalities, Long‐Term Outcomes, and Prognostic Factors
The Laryngoscope · 2025
DOI: 10.1002/lary.32079 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Laryngoscope, 2025. Verfasst von Yu-Jie Shen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Hypopharyngeal Neoplasms, Laryngeal Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Shanghai Minhang District Leading Talent Project, National Natural Science Foundation of China, Frontiers Science Center for Shanghai Municipality.
Abstract (Originalsprache)
Objectives cN3 larynx and hypopharynx cancer is rare with a poor prognosis. This study evaluates treatment approaches, effectiveness, and prognosis for these patients in real‐world settings. It aims to offer targeted and practical clinical guidance to enhance their treatment results and quality of life.
Methods
This retrospective cohort study (2014–2021) included 192 cN3 larynx and hypopharynx cancer patients from Eye & ENT Hospital of Fudan University. We collected detailed information on demographics, tumor characteristics, and treatment outcomes. The study focused on overall survival (OS), cancer‐specific survival (CSS), and disease‐free survival (DFS), using Kaplan–Meier and Cox regression analyses for independent prognostic analysis.
Results
This study encompassed 192 cN3 larynx and hypopharynx cancer patients, revealing a five‐year overall survival rate of 40.60%. Treatment modalities analyzed included Surgery + CRT, ICT + Surgery + CRT, ICT + CRT, Surgery alone, and CRT alone. Patients receiving surgery followed by CRT demonstrated the most favorable prognosis ( p < 0.0001) and the longest DFS ( p < 0.0001), while those undergoing monotherapy had the poorest outcomes. Induction chemotherapy (ICT) achieved a 70% primary tumor response rate and a 48% neck lesion response rate, with patients showing a response to ICT exhibiting superior OS, CSS, and distant metastasis rate (DMR) ( p < 0.05). Pathological type and primary tumor surgery were identified as independent prognostic factors for cN3 larynx and hypopharynx cancer.
Conclusion
This study shows that combined treatments, especially surgery followed by chemoradiotherapy, improve survival and prognosis for cN3 larynx and hypopharynx cancer patients. It highlights the importance of tailored treatments and notes better outcomes for those responding to ICT. Level of Evidence 3.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.
- Department of Radiation Oncology, Eye & ENT Hospital, Fudan University, Shanghai, China.
ORCID-Profile: Yu-Jie Shen, Tian Wang, Hong-Li Gong, Lei Tao, Ming Zhang
Förderung
- Shanghai Minhang District Leading Talent Project
- National Natural Science Foundation of China
- Frontiers Science Center for Shanghai Municipality
Zitieren
APA
Shen, Y. J., Wang, T., He, C. D., Gong, H. L., Xu, C. Z., Du, H. D., Tao, L., Zhang, M., & Zhou, L. (2025). Real‐World Insights Into cN3 Larynx and Hypopharynx Cancer: Treatment Modalities, Long‐Term Outcomes, and Prognostic Factors. The Laryngoscope. https://doi.org/10.1002/lary.32079
Vancouver
Shen YJ, Wang T, He CD, Gong HL, Xu CZ, Du HD, et al. Real‐World Insights Into cN3 Larynx and Hypopharynx Cancer: Treatment Modalities, Long‐Term Outcomes, and Prognostic Factors. The Laryngoscope. 2025. doi:10.1002/lary.32079
BibTeX
@article{Shen2025,
author = {Shen, Yu-Jie and Wang, Tian and He, Chang-Ding and Gong, Hong-Li and Xu, Cheng-Zhi and Du, Huai-Dong and Tao, Lei and Zhang, Ming and Zhou, Liang},
title = {Real‐World Insights Into cN3 Larynx and Hypopharynx Cancer: Treatment Modalities, Long‐Term Outcomes, and Prognostic Factors},
journal = {The Laryngoscope},
year = {2025},
doi = {10.1002/lary.32079}
}
EUVIMED